Table 4 AGGRECAN staining in 164 sarcomas and soft tissue neoplasms.

From: NFATc2-rearranged sarcomas: clinicopathologic, molecular, and cytogenetic study of 7 cases with evidence of AGGRECAN as a novel diagnostic marker

 

Type of staining

Tumor Subtype (n = 164)

Negative

Focally positive

Diffusely positive

Ewing sarcoma (58)

54 (93%)

4 (7%)

0

Mesenchymal chondrosarcoma (26)

3 (11%)

16 (61%)

7 (28%)

BCOR sarcoma (19)

19 (100%)

0

0

CIC sarcoma (26)

23 (88%)

2 (8%)

1 (4%)

Soft tissue myoepithelioma (10)

4 (40%)

3 (30%)

3 (30%)

Angiofibroma of soft tissue (1)

1 (100%)

0

0

Chordoma (8)

0

0

8 (100%)

Chondrosarcoma (2)

0

0

2 (100%)

Osteosarcoma (14)

1 (7%)

8 (57%)

5 (36%)

  1. Extent of tumor cell staining: negative (no expression or expression in <5%); focally positive (5–90%); diffusely positive (>90%).